Bottom line

• Nick Batia argues the Fed may return to liquidity injections sooner than many expect via reserve management purchases / T-bill QE / “QE light”, even while fighting inflation.
• He watches three under-the-radar money-market signals that show whether the system has enough liquidity.

1) Repo/SOFR spread

• SOFR is the secured overnight repo rate. If it pushes above the Fed’s policy corridor (e.g., IORB), it signals collateral/liquidity tightness.
• The spread has widened to 5 bps, the highest since tax day. Month-end, quarter-end, Thanksgiving and year-end rolls are likely pressure points.
• Similar spikes previously preceded the Fed’s T-bill purchases. That tool remains ready.

2) T-bill supply

• There are more than $7 trillion in T-bills, about 22% of marketable Treasuries.
• This could rise toward $10 trillion / roughly one-third. Short-term government debt must be funded in the cash/repo market.
• Banks may hoard reserves during stress rather than absorb more bills.

3) Bank reserves/GDP

• Reserves are about 9% of GDP, low versus much of the past decade outside COVID.
• Excess reserves barely existed before 2008; since then they are a trust/liquidity buffer. The 2019 repo crisis occurred near lows, followed by major QE.
• With GDP rising and reserves flat, the system needs more Fed liquidity over time.

Bonus: TGA

• The Treasury is rebuilding its TGA, implying more bill issuance. Batia sees this as a funding need, not a grand rate-manipulation scheme, though buybacks may help at the margin.

Takeaway

• If the Fed resumes T-bill purchases, they may need to be larger this time because Treasury issuance is larger.
• This is a key early signal for liquidity-sensitive assets like Bitcoin.

• The video analyzes how US markets historically react to different midterm outcomes – without political bias.
• Currently there is a Republican trifecta; prediction markets favor a Democratic majority in the House and Senate.

Historical market returns by political regime

• Best scenario since 1953: Democratic president with Republican Congress (median annualized return ~20%).
• Republican trifecta also positive: avg 13.3%, median 13.6%.
• Worst scenario: Republican president with fully Democratic Congress – avg 4.9%, median 4.0% (but returns remain positive: 12-month avg 4%).
• Including data back to 1928, the Great Depression skews results for divided regimes.
• Trifectas (Republican or Democratic) have historically performed similarly well (avg 9.8% vs. 9.0%; median 12.4% vs. 11.3%).

Risks and volatility

• Democratic trifectas also saw severe bear markets (e.g., 1937: -39%, 2008: -38.5%).
• Republican regimes show more extremes and higher volatility (e.g., 1987, 2020).
• The return distribution shows that lower averages are not just due to a few outliers.

Current term in comparison

• Trump's second term so far closely resembles his first (S&P 500 ~26% vs. ~20% after normalization).
• It currently outperforms Biden's term, which was in a bear market at this point.
• Bitcoin: Returns under Trump II and Biden are significantly lower than under Trump I and Obama II – likely due to macroeconomic issues (inflation, labor market).

Further statistics

• Highest Sharpe ratio: Lyndon B. Johnson (1.96), followed by Roosevelt (1945) and Clinton.
• Worst Sharpe ratio: Nixon's second term (-1.6).
• Heatmaps and Z-score charts visualize returns and risk by congressional composition.

Conclusion

• Historical data provide guidance, not guarantees. Uncertainty about the election outcome weighs on markets – polls can be wrong (see Brazil).

On October 29, 2025, Binance – the world's largest crypto exchange – fell victim to the largest hack in history (crypto and beyond). North Korea stole roughly $6.3–6.4 billion from Binance hot wallets across multiple blockchains, almost a quarter of the country's annual GDP.

How the Hack Happened

• Entry vector: A compromised laptop of a DevOps engineer (according to Binance). Binance later said there were additional points of breach.
• No private keys: The attackers did not obtain private keys but manipulated Binance's signing infrastructure – like using a bank's pen to sign checks without opening the vault.
• EIP-7702: On Ethereum, they used a novel technique: they pre-signed 50 transactions with different nonces. One of them converted the hot wallet into a smart account controlled by an attacker smart contract, sweeping all assets.
• Automation: New deposits were immediately drained as they arrived.
• Multiple chains affected: Ethereum, Bitcoin, Tron, Solana, XRP, etc. – indicating compromised infrastructure, not individual keys.
• Pre-hack tests: About 3 weeks earlier, attackers tested the EIP-7702 method using Tornado Cash-funded wallets.

Response and Freezes

• Swift freezes: Tether, Circle, Arbitrum Security Council and others froze nearly half the funds (~$3 billion). This is unprecedented – after the Bybit hack, initially less than 3% was frozen.
• Criticism: Circle and Tether's fast response was likely linked to their business relationship with Binance.
• Laundering and DeFi: The hackers used DeFi, including ThorChain, losing up to 10% on some swaps due to liquidity issues. MEV searchers earned ~$50 million.
• Aave freeze: Aave froze markets to prevent the use of stolen stablecoins.

ThorChain and the Controversy

• ThorChain became a major laundering channel for North Korea. In previous TraderTrader hacks, over 99% of daily volume came from laundering.
• FBI warning: FBI, Secret Service and IRS named ThorChain directly, urging node operators to block transactions with stolen funds.
• Centralization: ThorChain can be halted within minutes by a few node operators; becoming a node operator requires community approval – not very decentralized, according to Pablo.
• Controversial statements: JP Thor was quoted with a new Aston Martin helicopter with a DPRK flag, and argued North Korea might use the money to feed children – widely criticized as absurd and ignorant of the regime's reality.

TraderTrader & North Korea's Cyber Operations

• TraderTrader is a subgroup of North Korea's RGB (Reconnaissance General Bureau), responsible for major crypto hacks – from Ronin to Bybit and now Binance.
• Name origin: Trojanized trading apps as malware decoys in fake job interviews.
• Many subgroups: "Lazarus" has become a catch-all; different units have different TTPs.
• AI & automation: Laundering is highly automated; AI likely plays a role, though not confirmed.

Lessons and Recommendations

• Operational security is the weakest link – not smart contract bugs. ~90% of crypto organizations lack real OpSec expertise.
• Deploy EDR (Endpoint Detection and Response) e.g., CrowdStrike (~$150/year). Most infiltrations start on a laptop.
• Education: Leaders, security and compliance teams must understand the threat landscape (North Korea, TraderTrader etc.).
• Industry stance: The industry must stop enabling mass laundering. Decentralization and permissionlessness should not become excuses to fund dictatorships.
• Outlook: North Korea now holds more ETH than the Ethereum Foundation – a sad milestone.

Key takeaway: This hack was not a single exploit but a failure of operational security. The industry must prioritize OpSec before the next billion-dollar loss.

The Financial Times Revelation

• The Financial Times reported that OpenAI's annualized revenue is not $70 billion, but around $50 billion.
• This $20 billion gap caused a sell-off in Nvidia, CoreWeave, SoftBank, and Oracle stocks.

Why the $70 Billion Figure Existed

• Anthropic uses gross revenue (including cloud partner share), while OpenAI uses net revenue. To compare them, the market added the partner share back to OpenAI's number, creating the $70 billion estimate.
• OpenAI never officially confirmed that figure, yet it was priced into contracts and valuations across the industry.

OpenAI's Spending Commitments

• Internal plans show $856 billion in compute and infrastructure spending by 2030.
• Major contracts: $300 billion with Oracle (starting 2027), up to $250 billion with Microsoft Azure.
• Projected revenue for 2026 is only $36 billion – the commitments equal nearly 24 years of current revenue.
• Cumulative free cash flow from 2026 to 2030 is forecast at −$278 billion.

Who is Financing the Buildout?

• Nearly all construction is funded through private credit: GPU-backed loans, project finance, and bonds.
• Companies like Oracle ($156B debt), CoreWeave ($52B debt), and SoftBank ($40B bridge loan + junk bonds) are deeply leveraged.
• Lenders are betting that OpenAI's revenue will grow fast enough to cover the bills.

Conclusion

• OpenAI has raised massive capital ($122B in March, another $30B now being negotiated), but the gap between revenue and spending remains enormous.
• The entire AI infrastructure market faces a critical test: Can OpenAI deliver on expectations, or is a painful correction ahead?

The author reviews six S&P 500 stocks with unusual investment stories: a utility, a spin-off, AI infrastructure, a SpaceX stake, a software/financial services name, and an ETF provider. Core message: timing and risk-reward matter; most names are fair-to-expensive, and genuinely cheap opportunities are scarce.

The six core ideas

• Pinnacle West (PNW) – utility: Dividend yield 3.49%, P/E 20, growth 5–6% annually through 2030; Arizona growth and data centers support demand. $10B investment over 4 years. More attractive at recession/cyclical lows, not during euphoria.
• Solventum (SOLV) – 3M spin-off: P/E 11, profitable healthcare segments (surgical, dental, health IT). Spin-offs often carry debt/legacy issues and forced-selling pressure; interesting but currently too complicated.
• Generac (GNRC) – AI “picks and shovels”: Backup power for data centers; backlog $1.6B, industrial growth ~30%; Amazon contract potentially $8B. EPS ~9, P/E 20; 2028 EPS estimate 16 → 50%+ upside. A lower-risk way to play AI than direct AI bets.
• EchoStar (ECHO) – SpaceX at a discount? Spectrum sale to AT&T for $23B; owns 2% of SpaceX, split-adjusted entry at $42, stock around $90. UBS target $156 (~60% upside), but little value without SpaceX; risky, only for SpaceX believers.
• Gen Digital (GEN) – cheap but problematic: P/E 14, dividend 2%, $8B debt; brands Norton/Avast. Management appears more focused on survival than sustainable value creation.
• Invesco (IVZ) – valuation gap: P/E 10 vs. market ~30; benefits from rising markets and ETF assets. Fairly valued but reveals market risk: if the bubble bursts, 50–70% downside is possible, similar to the broader market.

Other quick takes

• Textron: too cyclical/risky.
• J.M. Smucker: cheap but no clear catalyst.
• Allegiant: fairly valued compounder, not a bargain.
• GoDaddy: risky, high churn and stock-based compensation.
• Avery Dennison: solid but expected returns too low.
• FedEx Freight: spin-off with financial engineering.
• REIT, Tyler Technologies, Hasbro: unattractive or fairly valued.

Conclusion

None of the ideas is clear deep value; the most interesting stories are Generac (AI infrastructure) and EchoStar (discounted SpaceX exposure), each with clear risks. The author stresses: buy when sentiment is poor, not when the story is obvious and priced in.

Key finding

• A study in Nature Aging from Dr. George Church’s lab (Harvard Medical School/Wyss Institute) reported that a single gene, the RNA splicing factor SRSF1, extended median lifespan in aged female mice by 14 % (108 days; from 778 to 886 days).
• SRSF1 likely improves RNA splicing fidelity and protein homeostasis without forcing cells into an embryonic state.

Contrast with Yamanaka factors

• The Yamanaka cocktail (Oct4, Sox2, Klf4, c-Myc) can reset cell age but risks loss of cell identity and teratomas.
• SRSF1 does not push cells toward pluripotency; it targets how cells edit their RNA messages.
• Major caveat: SRSF1 is a well-documented proto-oncogene; increased activity can help cancer cells escape cell death.

Cellular data

• A transcriptomic clock of 292 genes was trained on 133 human skin fibroblast lines (donors aged 1–96); 89 candidate genes were tested.
• SRSF1 was the most consistent hit; its baseline expression naturally declines with age.
• In fibroblasts from older donors (55, 65, 79 years), modeled rejuvenation reached 16 years, but with an ±9.5-year error margin.
• DNA methylation clocks were mixed; senescence markers were mixed (beta-galactosidase down, p16 unchanged); DNA damage markers were not significantly reduced.
• Crucially, cell identity was preserved, and pluripotency markers (Oct4, Sox2, Nanog) remained silent.

In vivo experiment

• An AAV8 vector carried mouse SRSF1 under a Tet-On switch, activated by doxycycline.
• Female mice received the vector at day 561 and induction at day 606; n=19 (10 treated, 9 controls).
• Median survival: 778 vs. 886 days.
• Caveats: female mice only; controls lived below the typical 850–900 days for C57BL/6; small exploratory cohort; individual physical performance measures were not significant after correction.
• Frailty: modeled score rose 44 % slower; onset of persistent frailty was delayed by about 123 days in the relevant subset.
• Liver: optimized DNA methylation clock showed −0.5 years, other clocks showed no significant difference; no histological reversal of liver fibrosis.
• Dosing mattered: high continuous SRSF1 expression did not help; only moderate pulsed induction supported survival.

Competition and clinical outlook

• Shift Biosciences shared a 2025 preprint on SB000, a single-gene candidate that reset epigenetic clocks in fibroblasts (Horvath-2013 −7.4 years; Dunedin Pace −0.132), but reported no survival data.
• The Church lab disclosed SRSF1’s sequence, pathways, and survival curves, filed patents, and founded Regulus Bio.
• AAV cargo limit: about 4.7 kb; SRSF1’s coding sequence is about 747 bp, so it fits with regulatory switches. But systemic AAV doses carry liver toxicity; Tet-On requires prolonged doxycycline with microbiome and mitochondrial risks.
• Life Biosciences ER-100 (AAV2, OSK, glaucoma) reported in 2026 that the first 3 patients tolerated 56 days of doxycycline induction; this says little about systemic safety.
• There are no human trials of SRSF1; because of its proto-oncogene risk, long toxicology studies would be needed. Realistically, future use would likely target localized tissues, not systemic longevity.

Bottom line

• SRSF1 is an important proof of concept for single-gene rejuvenation via RNA splicing.
• The open question is whether its repair benefits can be separated from its oncogenic risk.